Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-steroidal steroid receptor modulators.

Rogier C Buijsman1, Pedro H H Hermkens, Rachel D van Rijn

  • 1N.V. Organon, Medicinal Chemistry Department, P.O. Box 20, 5340 BH, Oss, The Netherlands.

Current Medicinal Chemistry
|May 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Lipopeptides as Orthoflavivirin Inhibitors with Low Micromolar Broad-Spectrum Antiorthoflaviviral Activity.

Journal of medicinal chemistry·2025
Same author

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.

Frontiers in oncology·2024
Same author

Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies.

Neuro-oncology advances·2023
Same author

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.

Journal of hepatology·2022
Same author

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.

Nature communications·2022
Same author

Mapping Arginase Expression with <sup>18</sup>F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2021
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
See all related articles

Researchers are developing non-steroidal ligands to selectively target nuclear receptors like PR, GR, AR, LXR, and FXR. This approach aims to reduce side effects and improve drug specificity by creating selective nuclear receptor modulators.

Area of Science:

  • Medicinal Chemistry
  • Molecular Pharmacology
  • Endocrinology

Background:

  • Steroidal nuclear receptors are key targets for drug development.
  • Existing steroidal ligands often exhibit cross-reactivity and undesirable side effects.
  • Non-steroidal ligands offer potential for improved selectivity and tailored pharmacological profiles.

Purpose of the Study:

  • To explore non-steroidal ligands with agonistic activity for specific nuclear receptors.
  • To discuss compounds that modulate Progesterone Receptor (PR), Glucocorticoid Receptor (GR), Androgen Receptor (AR), Liver X Receptor (LXR), and Farnesoid X Receptor (FXR).
  • To highlight the development of selective nuclear receptor modulators (SARMs or SPRMs).

Main Methods:

  • Literature review of recent advancements in non-steroidal ligand discovery.

Related Experiment Videos

  • Analysis of structure-activity relationships for selective receptor modulation.
  • Focus on compounds exhibiting full or partial agonistic effects.

    • Main Results:

    • Identification of non-steroidal ligands demonstrating selective agonistic activity across multiple nuclear receptors.
    • Characterization of compounds with modified binding modes and physicochemical properties.
    • Evidence for reduced cross-reactivity compared to traditional steroidal ligands.

    Conclusions:

    • Non-steroidal ligands represent a promising strategy for developing targeted therapies.
    • Selective nuclear receptor modulators offer potential for improved efficacy and safety profiles.
    • Further research into these ligands could lead to novel treatments for various conditions.